Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Heart dysfunction" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Use of remote ischemic conditioning to improve outcome after myocardial infarction
InactiveUS20110240043A1Promote resultsReduce riskOrganic active ingredientsDiagnosticsCardiac musclePost conditioning
The invention provides methods for reducing the incidence and / or severity and / or delaying the onset of heart dysfunction / failure and improving overall survival through the use of remote ischemic per-conditioning and post-conditioning.
Owner:HOSPITAL FOR SICK CHILDREN
Methods and compositions for treating cardiac dysfunctions
InactiveUS20090022729A1Treating and preventing hypertrophyBiocideDipeptide ingredientsCardiac dysfunctionProphylactic treatment
The present invention provides methods and pharmaceutical compositions for treating or preventing cardiac dysfunctions (e.g., cardiac hypertrophy, cardiac remodeling, or heart failure) in subjects who have or are likely to develop cardiomyopathies. Some of the methods are directed to therapeutic or prophylactic treatment of cardiac dysfunctions in subjects having undergone myocardial injuries such as cardiac ischemia / reperfusion or myocardial infarction. Typically, these methods comprising administering to the subjects a therapeutic composition comprising a compound which can specifically inhibit PAR1 mediated signaling or down-regulate the cellular level of PAR1.
Owner:THE SCRIPPS RES INST +1
Neukinase, a downstream protein of neuregulin
ActiveUS9580515B2Enhances neukinase expression and/or phosphorylationIncreased phosphorylationPeptide/protein ingredientsTransferasesKinase activityNeuregulin
The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to neukinase. In other aspects, the present invention further provides methods of identifying predisposition to cardiac dysfunction, methods of detecting the presence of neukinase, neukinase nucleic acid, methods of screening for agents which affect neukinase activity, and methods of modulating neukinase activity.
Owner:ZENSUN (SHANGHAI) SCI & TECH CO LTD
Transgenic Mouse Models for Diseases Caused by mtDNA Mutations and Related Methods
InactiveUS20100169985A1Improve developmentImprove satisfactionCompounds screening/testingDermatological disorderCochlear degenerationHeart disease
Animal models and methods wherein homoplasmic and heteroplasmic mtDNA mutation(s) are induced in an animal (e.g., a mouse) to cause or facilitate the development of a disorder (e.g., disease, malformation, defect, abnormality or other disorder). In at least some embodiments, the mtDNA mutation(s) will cause or facilitate the development of an age-related disorder, such as a cardiac disease, cardiomyopathy, muscle disease, cancer, abnormaly in tissues of high cellular turnover, heart dysfunction, graying of hair, alopecia, auditory function loss, cochlear degeneration, immune cell loss, anemia, male germ cell loss leading to lack of sperm and infertility, skeletal muscle mass loss (sarcopenia), neurodegeneration, increased presence of apoptotic markers, and loss of bone mass.
Owner:RGT UNIV OF CALIFORNIA
Usage of Roxadustat for treating sepsis
The invention relates to usage of Roxadustat in preparation of drugs for treating sepsis. In order to solve the problem of lack of therapeutic drugs for treating sepsis and organ dysfunction, such asheart dysfunction, liver heart dysfunction and the like, the invention provides novel usage of Roxadustat in preparation of drugs for treating sepsis as well as organ dysfunction, such as heart dysfunction, liver heart dysfunction and the like, thereby effectively reducing fatality rate of sepsis as well as treating organ dysfunction, such as cardiovascular dysfunction, liver dysfunction and the like, caused by sepsis.
Owner:NANJING CHILDRENS HOSPITAL
Application of tetrahydroberberrubine in preparation of heart protection medicine
ActiveCN113786405AImprove protectionBlock the remodeling processOrganic active ingredientsCardiovascular disorderCardiac dysfunctionPharmaceutical drug
The invention relates to an application of tetrahydroberberrubine in preparation of a heart protection medicine. Pharmacological experiments of tetrahydroberberrubine show that tetrahydroberberrubine can significantly improve cardiac dysfunction induced by pressure load, and has an obvious heart protection effect; and meanwhile, myocardial cell hypertrophy and interstitial fibrosis can be remarkably inhibited, the heart remodeling process is prevented, and the heart is prevented from entering the heart failure stage. In addition, the tetrahydroberberrubine compound is high in bioavailability, low in toxicity, stable and easy to produce, transport, store and take, and is a heart protection medicine with a wide application prospect.
Owner:HARBIN MEDICAL UNIVERSITY
Treatment of cardiac dysfunction
ActiveUS11071723B2Heterocyclic compound active ingredientsCardiovascular disorderCardiac dysfunctionPharmaceutical medicine
A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or pharmaceutically acceptable salt thereof or combination thereof.
Owner:ANAVEX LIFE SCI CORP
Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
ActiveUS9949992B2High expressionIncrease phosphorylation of kinasesOrganic active ingredientsNervous disorderCardiac dysfunctionPharmaceutical medicine
The present invention provides for methods and compositions for treating, reducing and / or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analog or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart tissue of the subject.
Owner:DUKE UNIV
Modeling neurological disorders and ataxias with cardiac dysfunction using bioengineered heart tissues
The disclosure provides a system for screening compounds for therapeutic cardiac effects in the cells, tissues and organoids of patients having diseases such as neurological diseases or disorders withsignificant cardiac comorbidities. The system comprises a medical device apparatus that can be suitable for a single-tier screen for cardio-active compounds that comprises a human ventricular cardiacanisotropic sheet (hvCAS) and human ventricular cardiac tissue strip (hvCTS), a two-tier system further comprising human ventricular cardiac organoid chamber (hvCOC), or a three-tier system still further comprising a medical device comprising multiple organoids, which include tissues or organoids of the same or different type (e.g., heart, liver, pancreas, kidney). Another aspect of the disclosure is the methods suitable for use with the systems, comprising screens for identifying compounds having cardiac effects on cells, tissues or organoids of patients having a non-cardiac disease exhibiting a cardiac effect, such as neurological diseases. The methods are further useful in assessing the toxicity of compounds to various cells, tissues or organoids of such patients.
Owner:NOVOHEART LTD
Use of remote ischemic conditioning to improve outcome after myocardial infarction
InactiveUS10136895B2Promote resultsReduce riskOrganic active ingredientsTourniquetsCardiac musclePost conditioning
The invention provides methods for reducing the incidence and / or severity and / or delaying the onset of heart dysfunction / failure and improving overall survival through the use of remote ischemic per-conditioning and post-conditioning.
Owner:HOSPITAL FOR SICK CHILDREN
Method of modulating the activity of calcium channels in cardiac cells and reagents therefor
InactiveUS20050049198A1High activityEnhance the activity of said RyR2Antibacterial agentsCompound screeningRyanodine receptorReceptor
The present invention relates generally to novel peptides that are capable of modulating the activity of calcium channels in cardiac cells. More specifically, the present invention provides a method of modulating the activity of a cardiac calcium channel comprising contacting a cardiac ryanodine receptor (RyR2) with an amount of a fragment of a dihydropyridine receptor (DHPR) polypeptide sufficient to modulate the activity of said RyR2, and determining the activity of said calcium channel. The inventive method is useful for the treatment of a range of disorders and diseases associated with cardiac dysfunction, particularly those diseases and disorders involving reduced cardiac output and / or aberrant excitation-contraction coupling, calcium overload, or calcium leakage, in cardiac cells.
Owner:AUSTRALIEN NAT UNIV
A traditional Chinese medicine composition for treating sepsis heart dysfunction
ActiveCN105287755BInhibit apoptosisReduces markers of myocardial damageUnknown materialsAntiinfectivesMortality rateBULK ACTIVE INGREDIENT
The invention discloses a medicine for treating sepsis myocardial dysfunction. The medicine consists of an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is prepared from the following raw materials: cassia twig, radix salviae miltiorrhizae, radix pseudostellariae, styrax ester, calculus bovis factitius and radix et rhizoma rhei. The traditional Chinese medicinal composition disclosed by the invention, which is prepared from the active ingredient and the excipient together, is capable of effectively improving the cardiac function of patients with sepsis myocardial dysfunction and reducing a death rate, a myocardial injury marker and an inflammatory mediator, and the traditional Chinese medicinal composition is free from an adverse reaction. The medicine fills a gap in the therapeutic field.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Treatment and prevention of cardiac dysfunction
InactiveUS20210069511A1Restoring cardiac functionReduce signalingSpinal electrodesExternal electrodesCardiac dysfunctionSympathetic nerve
Modulation of neural activity of a cardiac-related nerve at an interganglionic nerve branch in the sympathetic chain results in preferential reduction of sympathetic signals to the heart, thereby providing ways of treating and preventing cardiac dysfunction such as arrhythmias.
Owner:GALVANI BIOELECTRONICS LTD
Treatment of cardiac dysfunction
ActiveUS20190184172A1Good effectReduce usageSpinal electrodesHeart stimulatorsCardiac dysfunctionSympathetic nervous system
Modulation, preferably inhibition, of neurosignaling of a cardiac-related sympathetic nerve in the extracardiac intrathoracic neural circuit is effective in stabilizing cardiac electrical and / or mechanical function, thereby providing ways of treating or preventing cardiac dysfunction such as arrhythmias.
Owner:PRESIDIO MEDICAL INC
Application of histone deacetylase inhibitor in preparation of medicine for treating heart disease
PendingCN114306311AOrganic active ingredientsCardiovascular disorderCardiac fibrosisPosterior myocardium
The invention discloses application of a histone deacetylase inhibitor in preparation of a medicine for treating heart diseases, and belongs to the technical field of medical application of compounds. A mouse model with CDK13 knocked out of myocardium is constructed, and it is confirmed that deficiency of CDK13 in myocardium can cause cardiac dysfunctions such as dilated cardiomyopathy and heart failure; a molecular mechanism that CDK13 causes cardiomyopathy by regulating down-regulation of DMD gene expression is found. A histone deacetylase inhibitor No.1217 (the molecular formula of the histone deacetylase inhibitor No.1217 is C24H27N3O4) is used for performing drug treatment on a myocardial knockout CDK13 mouse, and the result shows that after continuous administration is performed for one month, the cardiac function, the cardiac fibrosis pathological process and the dystrophy protein level of the myocardial knockout CDK13 mouse are partially reversed. The invention finds an effective molecule and a treatment strategy for treating cardiomyopathy by targeting CDK13, and has important significance for treating heart disease.
Owner:TONGJI UNIV
Method for quantitatively evaluating cardiac function based on electrocardiogram U waves and T waves and device thereof
PendingCN111281373ANo discomfortNo side effectsDiagnostic recording/measuringSensorsHeart apexCardiac dysfunction
The invention discloses a method for quantitatively evaluating cardiac function based on electrocardiogram U waves and T waves and a device thereof, which relates to the field of cardiac function evaluation. By changing the cardiac apex pulsation state, the U-wave amplitude and the T-wave amplitude of an electrocardiogram in different cardiac apex pulsation states are measured, and the differencebetween the combined parameter of the U-wave amplitude and the T-wave amplitude and a normal value in a healthy state is compared, so that the cardiac function is evaluated. The method is simple, rapid, easy to operate and low in detection cost, a subject does not have any discomfort or side effect, and the method can be used for screening early cardiac dysfunction. The cardiac function evaluationequipment is small in size and convenient to carry and operate.
Owner:何乐
A method for establishing an eam mouse model induced by an autoantigen epitope
ActiveCN113907047BImprove stabilityMolding time is moderateImage enhancementImage analysisReceptorCardiomyocyte hypertrophy
The present invention provides a method for establishing a mouse model of autoimmune myocarditis (Experimental Autoimmune Myocarditis, EAM) induced by an autoantigen epitope. The relationship between AchR and autoimmune myocarditis is determined for the first time. Injection of AchR-Freund's complete adjuvant solution, AchR-Freund's incomplete adjuvant solution and immune booster to produce antibodies against cardiomyocyte M2 cholinergic receptors to induce autoimmune myocarditis, and the established model has cardiomyocyte hypertrophy , myocardial fibrosis and cardiac dysfunction. At the same time, with 18 F-FDG PET / CT myocardial metabolic imaging is the core, combined with echocardiography, HE staining of myocardial tissue sections, myocardial Mason staining and myocardial tissue immune antibody special staining to verify the characteristic changes related to the mouse model. Provide a new mouse model for further research on autoimmune myocarditis.
Owner:天津医科大学总医院空港医院
Compositions and methods for treating cardiac dysfunction
ActiveUS11111296B2Avoid dysfunctionAvoid lossMolecular entity identificationPeptide/protein ingredientsCardiac dysfunctionBiochemistry
The invention provides compositions and methods for treating cardiac dysfunction, particularly cachexia-associated or RAGE-associated cardiac dysfunction, using an anti-RAGE agent. The invention also provides compositions and methods for identifying therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing). The methods comprise designing or identifying agents that bind to functional sites identified on the RAGE polypeptide, wherein binding of agents to the functional site(s) inhibit RAGE-mediated cachetogenic signaling.
Owner:THE BROAD INST INC +1
Antisense compositions targeted to beta1-adrenoceptor-specific mRNA and methods of use
InactiveUS20030191080A1Inhibit and reduce expressionReduce inhibitionOrganic active ingredientsFungiNucleotideTherapeutic effect
Disclosed are antisense oligonucleotide, polynucleotide, and peptide nucleic acid compounds that specifically bind to mammalian mRNA encoding a beta1-adrenoceptor polypeptide and that are useful in the control and / or treatment of cardiac dysfunction, hypertension, hypertrophy, myocardial ischemia, and other cardiovascular diseases in an affected mammal, and preferably, in a human subject. The antisense compounds disclosed herein, and pharmaceutical formulations thereof, provide sustained control of beta1-adrenoceptor expression over prolonged periods, and achieve therapeutic effects from as little as a single dose. Administration of these antisense compositions to approved animal models resulted in a decrease in blood pressure, but no significant change in heart rate. Use of such antisense compositions in the reduction of beta1-adrenoceptor polypeptides in a host cell expressing beta1-adrenoceptor-specific mRNA, and in the preparation of medicaments for treating human and animal diseases, and in particular, hypertension and other cardiac dysfunction is also disclosed.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Application of kaempferol in preparation of medicine for treating or improving cardiac injury
PendingCN112618537AOrganic active ingredientsInorganic active ingredientsCardiac dysfunctionPharmaceutical drug
The invention provides an application of kaempferol in preparation of a medicine for treating or improving cardiac injury, and particularly provides an application of kaempferol in preparation of a medicine composition for treating cardiac injury or improving cardiac dysfunction, wherein the medicine composition can be used for treating cardiovascular complications caused by cancer chemotherapy medicines.
Owner:ZHEJIANG CANCER HOSPITAL
Method of personalized treatment for cardiomyopathy and heart failure and other related diseases by measuring renin activity, pro-renin, pro-renin receptor levels in blood
PendingUS20210262008A1Improve clinical outcomesMicrobiological testing/measurementDisease diagnosisDiseaseReceptor
Methods of using measured plasma renin activity assayed (PRA), plasma renin activity concentration (PRAC), active renin concentration (ARC), plasma renin activity concentration (PRAC) and / or active plasma renin concentration (APRC), pro-renin activity, (pro)-renin receptor (PRR) levels for diagnosing, prognosing, treating and monitoring heart failure (HF) or HF-associated conditions or other conditions that cause or are caused by altered (e.g., elevated) renin activity, pro-renin levels, PRR levels, PRC, APRC, and / or interaction of renin or pro-renin with PRR. These methods can be used for at-risk patients for personalized therapy of heart disease to reduce heart dysfunction progression, diminish HF, and prolong life. This technology stratifies patients with HF or those at risk for HF to determine the appropriate medication (agents that specifically interfere with plasma renin activity / pro-renin and / or PRR) or intervention and the appropriate dosage of medication to treat further HF progression.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use
InactiveUS7375185B2Reduce the amplitudeReduce impactVirusesPeptide/protein ingredientsDifferential effectsCardiac myosin
Owner:UNITED STATES OF AMERICA
Treatment of cardiac dysfunction
ActiveUS11369793B2Good effectReduce usageSpinal electrodesHeart stimulatorsCardiac dysfunctionSympathetic nerve
Modulation, preferably inhibition, of neurosignaling of a cardiac-related sympathetic nerve in the extracardiac intrathoracic neural circuit is effective in stabilizing cardiac electrical and / or mechanical function, thereby providing ways of treating or preventing cardiac dysfunction such as arrhythmias.
Owner:PRESIDIO MEDICAL INC
Treatment of cardiac dysfunction
PendingUS20220096424A1Heterocyclic compound active ingredientsCardiovascular disorderCardiac dysfunctionPharmaceutical medicine
A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or a pharmaceutically acceptable salt thereof or a combination thereof.
Owner:ANAVEX LIFE SCI CORP
Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure
In alternative embodiments, provided are methods for treating, ameliorating or protecting (preventing) congestive heart failure (CHF) or a diabetes-related cardiac dysfunction, comprising: providing a urocortin 2-encoding and / or a urocortin 3-encoding nucleic acid, transcript or message, or gene, operatively linked to a transcriptional regulatory sequence, optionally contained in an expression vehicle or a vector such as an adeno-associated virus (AAV), e.g., an AAV8 serotype; and administering to an individual or a patient in need thereof, such as a type 2 diabetic (T2DM), e.g., by IV administration, thereby treating, ameliorating or protecting against (preventing) the T2DM and / or the diabetes-related cardiac dysfunction in the individual or patient.
Owner:RGT UNIV OF CALIFORNIA
Application of pedf gene in the treatment of diabetic myocardial injury
Owner:SUN YAT SEN UNIV
Heart dysfunction early warning method and system
PendingCN114052674ATimely warningPlay a preventive roleCatheterDiagnostic recording/measuringCardiac dysfunctionBreath rate
The invention relates to a vital sign detection and analysis technology, and discloses a cardiac dysfunction early warning method and system so as to effectively carry out early warning on cardiac dysfunction. According to the invention, the atrial fibrillation frequency, the heart rate and the respiratory rate of a patient are comprehensively detected and analyzed, so the heart function value of the patient is obtained; big data analysis is conducted on the heart function value of the patient to judge the cardiac dysfunction condition of the patient; and thus, the cardiac dysfunction of the patient can be early warned in time, and the effect of taking precautions against calamity is achieved.
Owner:庚辰科技(宁波)有限公司
Application of RDH10 and/or prodrug thereof in preparation of medicine for treating and/or preventing diabetic myocardial injury
ActiveCN114452378AProtect heart functionProtective structurePeptide/protein ingredientsMetabolism disorderCardiac dysfunctionCardiac functioning
The invention provides application of RDH10 and / or a prodrug thereof in preparation of a medicine for treating and / or preventing diabetic myocardial injury. Experimental results show that along with development of diabetic myocardial injury, the myocardial RDH10 gene expression level is in a trend of increasing and then decreasing, and injection of RDH10 overexpression adeno-associated virus can restore the myocardial RDH10 expression of a diabetic patient to a healthy level, and the recovery of the level can effectively protect the cardiac function and myocardial structure of the diabetic patient, so that the myocardial RDH10 gene expression level is improved. The cardiac dysfunction and myocardial structure remodeling of the diabetic patients are delayed and / or inhibited, so that the diabetic myocardial injury is effectively prevented / treated.
Owner:SUN YAT SEN UNIV
Transgenic mouse models for diseases caused by mtDNA mutations and related methods
InactiveUS8203030B2Improve satisfactionMassive lossCompounds screening/testingDermatological disorderAge related diseaseCochlear degeneration
Animal models and methods wherein homoplasmic and heteroplasmic mtDNA mutation(s) are induced in an animal (e.g., a mouse) to cause or facilitate the development of a disorder (e.g., disease, malformation, defect, abnormality or other disorder). In at least some embodiments, the mtDNA mutation(s) will cause or facilitate the development of an age-related disorder, such as a cardiac disease, cardiomyopathy, muscle disease, cancer, abnormaly in tissues of high cellular turnover, heart dysfunction, graying of hair, alopecia, auditory function loss, cochlear degeneration, immune cell loss, anemia, male germ cell loss leading to lack of sperm and infertility, skeletal muscle mass loss (sarcopenia), neurodegeneration, increased presence of apoptotic markers, and loss of bone mass.
Owner:RGT UNIV OF CALIFORNIA
Compositions and methods for treating septic cardiomyopathy
InactiveUS20210128596A1Improve mitochondrial functionIncrease contractilityOrganic active ingredientsPharmaceutical delivery mechanismNatural sourceCardiac dysfunction
Methods and compositions are provided for treating sepsis-associated cardiac dysfunction, specifically sepsis-induced cardiomyopathy, and for protecting the heart from sepsis-associated dysfunction and improving cardiac function in subjects having sepsis. These methods include administering compositions comprising secoisolariciresinol diglucoside (SDG) or related compounds, obtained from natural sources, such as flaxseed, or generated synthetically.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com